IDH1 and acute myeloid leukemia: Structure-based virtual screening of 3957 drug-like compounds from DrugBank identified three top-ranking FDA-approved candidates (DB16703, DB08512, and DB16047) with strong binding affinity across the three selected AML targets: LSD1, BCL2, and mutant IDH1 (R132H).